U.S. markets closed

AVROBIO, Inc. (AVRO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.34-0.31 (-3.21%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close9.65
Open9.43
Bid9.40 x 900
Ask9.70 x 1200
Day's Range9.04 - 9.50
52 Week Range7.45 - 22.40
Volume962,179
Avg. Volume468,144
Market Cap397.372M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Gene Therapy Companies Undervalued, Positioned for Upside
    TipRanks

    Gene Therapy Companies Undervalued, Positioned for Upside

    Pharmaceutical companies can trade sideways for years, and may see a spike every now and then due to positive announcements or an FDA approval update. The newest subset of the biotech industry, known as gene therapy companies, has been multiplying at an astonishing rate. As a result, they have many new stocks listed to capital markets. These companies have recently piqued the interest of investors, and analysts are weighing in. Many individuals are born with disorders for which there is no cure,

  • How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks
    Barrons.com

    How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks

    Cancer scares are dissipating from experimental treatments that insert functioning genes in patients whose damaged copies cause sickle cell, hemophilia and other congenital diseases.

  • Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?
    Zacks

    Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?

    AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.